Opthea Information

Opthea (ASX/NASDAQ:OPT) is an Australian biotechnology pioneer focused on efficiently advancing a validated asset through a clinical program to deliver the first disease-modifying treatment for LAM, or lymphangioleiomyomatosis, a rare disease largely affecting women. The company’s lead asset has already been studied in approximately 2,000 patients in prior late-stage development. This has established a strong understanding of its safety and biological activity in humans. LAM is driven by aberrant signaling of the proteins VEGF-C and VEGF-D, which the asset directly targets. The proven biology and prior validation enable a focused and capital-efficient path toward clinical proof-of-concept.